Prevention of arthropathy in haemophilia - intensive on-demand treatment, UK perspective.
In the past, there were only minimal studies aimed at establishing the dose of concentrate required for treating an acute joint bleed in patients without inhibitors. The cost of treatment with bypassing agents consumes huge economic resources and therefore it is important to have rigorous studies to establish rational dosing. Both the FEIBA NovoSeven Comparative study and the comparative dosing study have been bold attempts to clarify treatment regimens for managing joint bleeds in patients with inhibitors. As a very challenging situation in which to conduct research, it is important that such endeavour continues.
Lee
C A
CA
Oxford Haemophilia and Thrombosis Centre, Oxford, UK. ProfCALee@hotmail.com
D000293:Adolescent; D000328:Adult; D001779:Blood Coagulation Factors / Q000191:economics / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D003029:Coagulants / Q000008:administration & dosage* / Q000191:economics; D005169:Factor VIII / Q000008:administration & dosage* / Q000191:economics; D015942:Factor VIIa / Q000627:therapeutic use; D006395:Hemarthrosis / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control*; D006467:Hemophilia A / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use; D006113:United Kingdom; D055815:Young Adult
D001779:Blood Coagulation Factors; D003029:Coagulants; D011994:Recombinant Proteins; C025667:prothrombin complex concentrates; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa